The Acme Universal Safezone 9 IPO is a closed SME Bookbuilding offer (Fresh capital only) that opened on 28 September 2026. The Acme Universal Safezone 9 IPO closed on 30 September 2026, with an issue price of ₹71 per share. The Acme Universal Safezone 9 IPO has a face value of ₹10 and a lot size of 1,600 shares. The Acme Universal Safezone 9 IPO size aggregates up to ₹36 crore, listing on BSE SME on 6 October 2026. The Acme Universal Safezone 9 IPO allotment was scheduled for 1 October 2026.
On the financial front, the Acme Universal Safezone 9 IPO reported revenue of ₹211 crore for 31 Mar 2026, compared with ₹191 crore for 31 Mar 2025. The Acme Universal Safezone 9 IPO PAT was ₹6 crore against ₹1 crore. The Acme Universal Safezone 9 IPO EBITDA stood at ₹15 crore with a 7.36% margin. The Acme Universal Safezone 9 IPO net worth as of 31 Mar 2026 was ₹53 crore.
Always verify The Acme Universal Safezone 9 IPO details and GMP data with the official offer document before investing in the Acme Universal Safezone 9 IPO.
Financial Summary
Amount in ₹ Crore
Metric
31 Mar 2026
31 Mar 2025
31 Mar 2024
Total Assets
147
134
119
Revenue
211
191
182
PAT
6
1
8
EBITDA
15
10
15
Net Worth
53
47
42
Reserves
39
42
38
Total Borrowing
58
50
45
Acme Universal Safezone 9 IPO Financials FAQs
Revenue of Acme Universal Safezone 9 (Amount in ₹ Crore) — 31 Mar 2026: 211; 31 Mar 2025: 191; 31 Mar 2024: 182. Profit after tax (PAT) — 31 Mar 2026: 6; 31 Mar 2025: 1; 31 Mar 2024: 8.
EBITDA of Acme Universal Safezone 9 (Amount in ₹ Crore) — 31 Mar 2026: 15; 31 Mar 2025: 10; 31 Mar 2024: 15. The EBITDA margin is 7.36%.
Total assets — 31 Mar 2026: 147; 31 Mar 2025: 134; 31 Mar 2024: 119. Net worth — 31 Mar 2026: 53; 31 Mar 2025: 47; 31 Mar 2024: 42. Reserves & surplus — 31 Mar 2026: 39; 31 Mar 2025: 42; 31 Mar 2024: 38. (Amount in ₹ Crore)
Total borrowing of Acme Universal Safezone 9 (Amount in ₹ Crore) — 31 Mar 2026: 58; 31 Mar 2025: 50; 31 Mar 2024: 45. Debt-to-equity ratio: 1.10.
The financials shown for Acme Universal Safezone 9 IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.